Revolution Medicines is a clinical-stage oncology company that develops targeted cancer treatments focused on RAS-driven tumors. The company's pipeline includes direct RAS inhibitors designed to target specific RAS mutations, which can be used alone or combined with companion inhibitors that address cooperating pathways in RAS-dependent cancers. Its lead candidates are in clinical and late-stage trials, with several programs evaluating combinations for pancreatic and other solid tumor indications.

entry readiness 31 · NOT READY · exit proximity 0

Value area 176.25–211.05 · 77% of 120d volume overhead · heavy supply